Mosapride Citrate, developed by Takeda, is a gastroprokinetic agent that enhances gastrointestinal motility, and exerts anti-inflammatory effects on the GI tract. It acts as a 5-HT4 receptor agonist and 5-HT3 receptor antagonist.
|Mechanism of Action||Mosapride Citrate is a 5-HT4 receptor agonist and 5-HT3 receptor antagonist. It is also used as an antispasmodic.|
|Eukaryotic Cell Culture Applications||Mosapride Citrate was able to induce the formation of a functional organ-like cluster, a "gut" from mouse embryonic stem cells using an embroid body culture system. If it was added during the formation of the embryoid body at a concentration of 1-10 uM, it induced the formation of this organ-like cluster, which had dense distributions of interstitial cells and smooth muscle cells, and was able to spontaneously contract on its own (Takaki et al 2001). Mosapride Citrate was used in a rapid, high-throughout luminescent screening assay to measure cytochrome P4500 induction. The induction of the isozymes 1A2, 2B6, 2C9, and 3A4 in cryopreserved human hepatocytes (HMC424, 478, and 493). Authors found the compound promoted CYP1A2, 2B6, and 3A4 activities (Kim et al, 2015).|
|References||Currean MP and Robinson DM (2008) Mosapride in gastrointestinal disorders. Drugs. 68(7):981-991 Kim YH et al. (2015) Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay. Biomol Ther (Seoul) 23(5):486-492 PMID 26336590 Yoshida N, Omoya H, Kato S, Ito T (1993) Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals.Arzneimittelforschung 43(10):1078-1083 PMID 8267674|